To pretreat or not to pretreat? The experience of three Italian Psoriasis centres on the use of premedication with Infliximab

J Eur Acad Dermatol Venereol. 2016 Oct;30(10):e55-e57. doi: 10.1111/jdv.13298. Epub 2015 Sep 3.

Authors

F Bardazzi¹, F Savoia², V Di Lernia³, V Tengattini¹, R Balestri¹, A Patrizi¹, M Magnano⁴

Affiliations

¹ Division of Dermatology, Department of Specialistic, Clinical and Experimental Medicine, University of Bologna, Bologna, Italy.
² Dermatology Unit, Azienda Unità Sanitaria Locale della Romagna, Ravenna, Italy.
³ Dermatology Unit, Arcispedale Santa Maria Nuova, IRCCS, Reggio Emilia, Italy.
⁴ Division of Dermatology, Department of Specialistic, Clinical and Experimental Medicine, University of Bologna, Bologna, Italy. michela.magnano@gmail.com.

PMID: 26337536
DOI: 10.1111/jdv.13298

No abstract available

Publication types

Letter
Multicenter Study

MeSH terms

Adult
Aged
Dermatologic Agents / administration & dosage
Dermatologic Agents / therapeutic use*
Female
Humans
Infliximab / administration & dosage
Infliximab / therapeutic use*
Italy
Male
Middle Aged
Premedication
Psoriasis / drug therapy*
Young Adult

Substances

Dermatologic Agents
Infliximab